WO2011067758A3 - Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae - Google Patents

Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae Download PDF

Info

Publication number
WO2011067758A3
WO2011067758A3 PCT/IL2010/001009 IL2010001009W WO2011067758A3 WO 2011067758 A3 WO2011067758 A3 WO 2011067758A3 IL 2010001009 W IL2010001009 W IL 2010001009W WO 2011067758 A3 WO2011067758 A3 WO 2011067758A3
Authority
WO
WIPO (PCT)
Prior art keywords
multimers
streptococcus pneumoniae
immunogenic fragments
pneumoniae proteins
pneumoniae
Prior art date
Application number
PCT/IL2010/001009
Other languages
English (en)
Other versions
WO2011067758A2 (fr
Inventor
Yaffa Mizrachi-Nebenzahl
Michael Tal
Ron Dagan
Maxim Portnoi
Original Assignee
Protea Vaccine Technologies Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protea Vaccine Technologies Ltd. filed Critical Protea Vaccine Technologies Ltd.
Publication of WO2011067758A2 publication Critical patent/WO2011067758A2/fr
Publication of WO2011067758A3 publication Critical patent/WO2011067758A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6043Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des fragments immunogènes, y compris des variantes et des analogues dérivés de protéines de Streptococcus pneumoniae (S. pneumoniae), des multimères de polypeptides et des protéines de fusion comprenant de tels polypeptides, et des vaccins comprenant de telles entités immunogènes. L'invention concerne notamment l'utilisation de tels vaccins pour provoquer une immunité protectrice contre S. pneumoniae.
PCT/IL2010/001009 2009-12-02 2010-12-01 Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae WO2011067758A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26577209P 2009-12-02 2009-12-02
US61/265,772 2009-12-02

Publications (2)

Publication Number Publication Date
WO2011067758A2 WO2011067758A2 (fr) 2011-06-09
WO2011067758A3 true WO2011067758A3 (fr) 2011-10-13

Family

ID=43983528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2010/001009 WO2011067758A2 (fr) 2009-12-02 2010-12-01 Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae

Country Status (1)

Country Link
WO (1) WO2011067758A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201403702SA (en) 2009-06-29 2014-09-26 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
MY163871A (en) 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
WO2015189422A1 (fr) 2014-06-12 2015-12-17 Universidade Do Porto - Reitoria Vaccin pour hôtes immunodéprimés
EP2955194A1 (fr) * 2014-06-12 2015-12-16 Universidade do Porto - Reitoria Vaccin néonatal
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077021A2 (fr) * 2001-03-27 2002-10-03 Chiron Srl. Proteines et acides nucleiques de streptococcus pneumoniae
US20050187718A1 (en) * 2001-09-21 2005-08-25 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from Streptococcus pneumoniae

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4539205A (en) 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA2017507C (fr) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
HU219056B (hu) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5869058A (en) 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
KR100578317B1 (ko) 1997-05-20 2006-05-11 갈레니카 파마슈티칼스 인크. 면역보강성 및 면역자극 활성을 갖는 트리테르펜 사포닌유사체
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
PT1042001E (pt) 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
EP0980571A2 (fr) 1998-03-04 2000-02-23 Koninklijke Philips Electronics N.V. Dispositif d'affichage
PL354714A1 (en) 1998-04-09 2004-02-09 Smithkline Beecham Biologicals S.A. Adjuvant compositions
WO1999056776A2 (fr) 1998-05-07 1999-11-11 Corixa Corporation Composition d'adjuvant et procedes d'utilisation de celle-ci
MXPA01006191A (es) 1998-12-14 2003-07-21 Europ Lab Molekularbiolog Metodos y dispositivos para aplicar substancias a un soporte, especialmente monomeros para la sintesis de combinacion de bibliotecas de moleculas.
US6843781B2 (en) 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
EP2275125A3 (fr) 2002-04-02 2011-03-09 Ben Gurion University Of The Negev Research And Development Authority Vaccins contre le streptococcus pneumoniae à base de protéine
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
MX2010001284A (es) 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Vacunas contra la influenza con multiepitope multimerico.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077021A2 (fr) * 2001-03-27 2002-10-03 Chiron Srl. Proteines et acides nucleiques de streptococcus pneumoniae
US20050187718A1 (en) * 2001-09-21 2005-08-25 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from Streptococcus pneumoniae

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALONSODEVELASCO E ET AL: "STREPTOCOCCUS PNEUMONIAE: VIRULENCE FACTORS, PATHOGENESIS, AND VACCINES", MICROBIOLOGICAL REVIEWS, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 59, no. 4, 1 December 1995 (1995-12-01), pages 591 - 603, XP000946788, ISSN: 0146-0749 *

Also Published As

Publication number Publication date
WO2011067758A2 (fr) 2011-06-09

Similar Documents

Publication Publication Date Title
WO2009016639A3 (fr) Vaccins contre la grippe à multiples épitopes multimères
CA2830786C (fr) Proteines de fusion et polyvaccins comprenant la proteine e et la piline a d'haemophilus influenzae
IL263249B (en) A polypeptide isolated from btv virus which causes an immune response in an animal and a polypeptide containing a DNA segment that codes for an epitope or an antigenic determinant of the btv polypeptide
WO2010150242A3 (fr) Peptides de streptococcus pneumoniae immunogènes et multimères peptidiques
WO2012069655A3 (fr) Modules de coiffage n-terminal améliorés pour des protéines de répétitions d'ankyrine conçues
WO2011067758A3 (fr) Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae
EP3988115A3 (fr) Compositions à base de protéine f du vrs et procédés de fabrication associés
WO2011032161A3 (fr) Vaccins dirigés contre les cellules de langerhans
ZA201200832B (en) Immunogenic composition comprising antigenic s. aureus proteins
WO2010149752A3 (fr) Nouvelles compositions
MX2009001778A (es) Peptidos pcpa inmunogenicos y usos de los mismos.
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
WO2008148104A8 (fr) Nouvelles vlp dérivées de cellules qui n'expriment pas une matrice virale ou une protéine du noyau
WO2013040093A3 (fr) Compositions de peptide-2 de type glucagon et leurs procédés de fabrication et d'utilisation
WO2008124646A3 (fr) Utilisation de protéines amyloïdes en tant qu'échafaudages pour des vaccins
WO2010039224A3 (fr) Séquences du virus syncytial respiratoire (rsv) destinées à l'expression de protéines et aux vaccins
WO2007115059A3 (fr) Vaccin anti-streptocoques
WO2010019262A3 (fr) Vaccin polyvalent
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
BR112015014727B8 (pt) Composição imunogênica, vacina, e, uso de uma composição imunogênica
MX2011007456A (es) Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
WO2008134643A3 (fr) Antigènes de trypanosome, compositions de vaccins et procédés associés
IL232867B (en) Amyloid-binding polypeptide and chimeric protein containing it, pharmaceutical preparations containing the polypeptide or chimeric protein, methods for their preparation and uses
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10801465

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10801465

Country of ref document: EP

Kind code of ref document: A2